Distinct Expression and Function of the Novel Mouse Chemokine Monocyte Chemotactic Protein-5 in Lung Allergic Inflammation

By Gui-Quan Jia,* Jose A. Gonzalo,* Clare Lloyd,* L. Kremer,† Lei Lu,§ C. Martinez-A,§ B.K. Wershil,§ and J.C. Gutierrez-Ramos*

From *The Center for Blood Research, Inc., and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115; †Department of Immunology and Oncology, Centro Nacional de Biotecnologia, 28049-Madrid, Spain; and §The Combined Program in Pediatric Gastroenterology and Nutrition, The Children's Hospital and the Massachusetts General Hospital, Boston, Massachusetts 02115

Summary

We have cloned a novel mouse CC chemokine cDNA from the lung during an allergic inflammatory reaction. The protein encoded by this cDNA is chemotactic for eosinophils, monocytes, and lymphocytes in vitro and in vivo. Based on its similarities in sequence and function with other CC chemokines, we have named it mouse monocyte chemotactic protein-5 (mMCP-5). Under noninflammatory conditions, expression of mMCP-5 in the lymph nodes and thymus is constitutive and is generally restricted to stromal cells. Neutralization of mMCP-5 protein with specific antibodies during an allergic inflammatory reaction in vivo resulted in a reduction in the number of eosinophils that accumulated in the lung. Moreover, mMCP-5 mRNA expression in vivo is regulated differently from that of other major CC chemokines in the lung during the allergic reaction, including Eotaxin. The presence of lymphocytes is essential for expression of mMCP-5 by alveolar macrophages and smooth muscle cells in the lung, and the induction of mMCP-5 RNA occurs earlier than that of the eosinophil chemokine Eotaxin during allergic inflammation. In contrast to Eotaxin, mRNA for mMCP-5 can be produced by mast cells. From these results, we postulate that mMCP-5 plays a pivotal role during the early stages of allergic lung inflammation.

The late phase of an asthmatic reaction is mediated by a swarm of leukocytes that are recruited to the lung by cytokines and chemotactic factors (1). The mechanism(s) by which the different populations of leukocytes are recruited and how they regulate the attraction and function of other leukocytes present at the inflammatory site is poorly understood. However, there is evidence to suggest that the accumulation of eosinophils at sites of allergic reactions may be directly associated with the presence of lymphocytes and with the production by T cells of cytokines, which are known to stimulate eosinophil maturation, activation, and survival, or to modulate the expression of adhesion molecules (2, 3).

At the present time, the accepted paradigm for leukocyte extravasation is that the selective homing of particular circulating leukocytes into inflamed tissues takes place via the generation of chemotactic gradients created by chemoattractants or by specific cytokines termed chemokines (4, 5). Most chemokines can be grouped as members of either the CXC (α) or CC (β) family to denote the spacing of the first two cysteine residues of the mature proteins. The CXC chemokine family seems to act preferentially on neutrophils and includes, among others, platelet factor 4, NAP-1/IL-8, gro, IP-10, and ENA-78. The CC family has been described as attracting several leukocyte subsets, but not neutrophils, and includes macrophage inflammatory protein (MIP)1-10, -β, monocyte chemotactic protein-1 (MCP-1)/JE, MCP-2, MCP-3, Eotaxin, and RANTES (6). The relevance of chemokines in the migration of leukocytes to inflammatory sites in vivo has been demonstrated in various experimental systems of differing complexity (7–9).

Because of their broad chemotactic specificities, CC chemokines could play a central role in the development and maintenance of the leukocytic infiltration found in the lung during allergic inflammation (eosinophils, lymphocytes, monocytes, etc., and lack of a significant and/or predominant infiltration of neutrophils). We and others have

Abbreviations used in this paper: BMCMC, bone marrow–cultured mast cells; h, human; m, mouse; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; RT, reverse transcriptase.
identified and studied several CC chemokines, including mouse Eotaxin, in the lungs of mice that were rendered eosinophilic by repeated exposure to aerosolized OVA (10–13).

The work reported here represents our continued efforts in the identification and study of CC chemokines that could be integral in promoting the complex leukocyte infiltration that is present in the lung during allergic reactions. We have isolated a novel cDNA from mouse hyper eosinophilic lungs by PCR amplification based on consensus sequences that are present in CC chemokine genes. This novel mouse CC chemokine has strong homology with human (h)MCP-1. The chemotactic activity of the protein encoded by this gene in vitro, as well as after in vivo administration, and the regulation of the expression and function of this gene during lung eosinophilia are presented here.

Materials and Methods

Mice and In Vivo Procedures. 8–10-wk-old male and female C57BL/6j and RAG-1–deficient mice were purchased from the Jackson Laboratory (Bar Harbor, ME), and kept in the Center for Blood Research Specific Pathogen Free mouse facility (Harvard Medical School). CD3e-transgenic mice (14) were kindly provided by Dr. C. Terhorst (Beth Israel Hospital, Boston, MA). OVA-induced pulmonary eosinophilia (Sigma Immunochimicals, St. Louis, MO) was generated in these mice (three individual experiments, n = 10) as previously described (10).

Peritoneal recruitment assays in vivo with mouse (m)MCP-5 protein were performed after injection of 400 or 800 µl of mMCP-5 recombinant protein–containing conditioned media (see below) or control conditioned media. At different time points after injection (0, 1, 2, 3, or 4 h), (three individual experiments, n = 8–13 for test and control mice per time point and dose), leukocytes recovered from peritoneal lavage were analyzed and enumerated. For the coinjection experiments, bacterial mMCP-5 (0.5 µg/200 µl per mouse; Peprotech, Inc., Rocky Hill, NJ) was administered intraperitoneally simultaneously with either 400 or 800 µl of mMCP-5 containing conditioned media. In one series of experiments, lower doses of Eotaxin (0.2 µg/mouse) were coinjected with lower doses of mMCP-5 (100 µl/mouse). Control mice were injected intraperitoneally with (a) mMCP-5 protein and control conditioned media; (b) PBS and mMCP-5–containing conditioned media; and (c) PBS and control conditioned media. All doses and volumes were exactly the same as those given to test mice. At different time points after coinjection of mMCP-5–containing conditioned media and mMCP-5 recombinant protein–containing conditioned media (1, 2, 3, or 4 h; three individual experiments, n = 4–12, for test and control mice per time point and dose), recovered cells from the peritoneum were analyzed. In one series of blocking experiments, mice were injected with affinity-purified neutralizing monoclonal antibodies against mMCP-5 (20 µg/mouse, i.v.) 30 min before OVA administration on days 20 and 21, and then analyzed 3 h after allergen challenge on day 21. OVA-treated control mice were injected with the same amount of control Ab (purified rabbit Ig fraction; Dako Corp., Carpinteria, CA) at the time points indicated during treatment.

Cloning of cDNA by Reverse Transcription (RT)-PCR. A partial cDNA fragment of the mMCP-5 gene was cloned from RNA extracted from eosinophilic lungs of OVA-sensitized mice (10). To clone the full-length mouse mMCP-5 cDNA, we followed the same two-step PCR amplification strategy that we used recently to clone mouse Eotaxin (10). Specific primers used for every step during the cloning were as follows: first step round 1, 5′ primer 1 (a chimeric primer containing (dT)15 and sequence of the Tp promoter: 5′-TATAAGGCATCATAGGATTTTGTGTTTTTTTTTTTTT) and 3′ primer 1 (5′-CCTCTATTACCGTTATGGTC; first step round 2, 5′ primer 2 (sequence of the Tp promoter: 5′-TATAAGGCATCATAGG) and 3′ primer (designed nested to first 3′ primer from the sequence of the cloned fragment: 5′-ACAGCTTCGCCGGAGCATCGT); second step round 1, primers 1 and gene specific 5′ primer (designed from the 5′ sequence of the cloned fragment: 5′-AGAGACACTGGTTCCTGCAG); second step round 2, primers 2 and a second gene specific primer (a primer containing sequences nested to first 5′ primer: 5′-TCTCCCTCCACCATGCAGA).
IgM, or Thy1.2, conjugated with FITC or PE (PharMingen, San Diego, CA). Dead cells were excluded by propidium iodide (Sigma) incorporation. Flow cytometry data were acquired with a FACScan® cytometer, and were analyzed with CELLQUEST software.

**Generation and Screening of Polyclonal Sera and mAbs Anti-mMCP-5.** Polyclonal sera against mMCP-5 was generated according to standard methods using the synthetic peptide CADPKEKWVKNSINHLDKTS, covering amino acids 52-71 in the mMCP-5 peptide sequence, coupled to KLH (Pierce Chemical Co., Rockford, IL; 17). Rabbit serum was first depleted of anti-mouse IgG antibodies by passage over a mouse IgG column, and anti-mMCP-5 antibodies were purified from the flowthrough on a mMCP-5 peptide (52-71) affinity column. Antibody titers were determined by ELISA.

10-wk-old Wistar rats were immunized in the hind footpad with the KLH-coupled mMCP-5 peptide, and cell fusions were performed as described before (18). Positive supernatants were studied in Western blot analysis against mMCP-5 that was produced by transfected cells. A total of nine mAbs were obtained and characterized by Western blotting and immunostaining. Four mAbs recognized mMCP-5 epitopes that were present in frozen sections. One of those, ZY2A11, was used for the experiments described here.

Affinity-purified rabbit polyclonal antibodies and rat mAbs were shown to recognize a specific band in a Western blot against mMCP-5-containing conditioned media, but not against the conditioned media of mock-transfected cells (data not shown). This band was specifically competed by preincubation of the Ab preparations with the mMCP-5 (52-71) peptide used for immunization (data not shown).

**Southern and Northern Blots.** Both were performed following standard methods and the following probes: mMCP-5 (0.29-kb fragment cloned from 5′ RACE), Eotaxin (10), RANTES (19), and MCP-1 (20).

**Measurement of mMCP-5 and mEotaxin mRNA Expression by RT-PCR.** For RT-PCR, we followed the methods described before (10). The specific primers for mMCP-5 used in PCR are as following: 5′ primer, 5′-TCTCCCTCCACCATGCAGAG and 3′ primer, 5′-CTCTTATCCAGTATGGTCC.

The macrophage cell lines RAW267.8 and P388D1 were cultured with TNF-α (20 ng/ml) for 24 h, and the endothelial cell line bEnd3 and the fibroblast cell line NIH3T3 were cultured with PMA/IONOMycin (10:500 ng/ml) for 8 h. Macrophages were freshly isolated from mouse peritoneal cavity 48 h after infection of thioglycollate (1 ml/mouse), and were cultured in vitro with TNF-α (20 ng/ml) or IFN-γ respectively for 24 h.

The mast cells studied included a cloned, growth factor-independent mast cell line (CLMC/C57.1 [21]) or primary cultures of bone marrow–cultured mast cells (BMCMC). Primary cultures of BMCMC were generated from bone marrow cells isolated from BALB/c mice as described previously (21). BMCMC were used for experiments at 4–6 wk, at which time mast cells represented >99% of the cells, as determined by neutral red staining.

**Immunohistochemical Phenotyping and Quantitation of Leukocytes.** The number and type of leukocytes migrating in response to mMCP-5 recombinant protein or to both chemokines (mMCP-5 protein and mMCP-5 recombinant protein) in peritoneal lavage fluid was determined as described before (10). To determine the number of lymphocytes, monocytes, and macrophages, slides were stained with mAb against Thy 1.2 (53-2.1), Mac-1 (M1/70), CD45R/B220 (RA3-6B2) from PharMingen, and Moma-2 from Biosource International (Camarillo, CA) using an avidin/biotin staining method as described before and counterstained with hematoxylin.

The number of leukocyte subtypes was determined in four high power fields (magnification of 400; total area = 0.5 mm²) per slide (duplicate slides per mouse and time point were examined). Monocytes and macrophages were distinguished from lymphocytes on the basis of expression of Mac-1 and Moma-2 on their surface and from each other, based on the difference in size and granularity observed after Giemsa counterstaining by light microscopy or by flow cytometry.

**Immunohistochemical Staining of Lungs and Lymphoid Tissue for mMCP-5.** Sections of lungs from OVA-treated mice and of inguinal LN and thymi from unchallenged mice were fixed and stained with an mAb directed against mMCP-5 using an avidin/biotin staining method. Sections were overlaid with 20% normal rabbit serum in PBS for 15 min. Lungs were incubated with neat anti-mMCP-5 (ZY2A11) culture supernatant, and LN and thymi were incubated with anti-mMCP-5 ascites at 1/100, both overnight at 4°C. Endogenous peroxidase was subsequently blocked. Bound mAb was visualized by incubation with biotinylated rabbit anti-rat Ig diluted in 10% normal mouse serum PBS, and then with streptavidin peroxidase complex prepared according to manufacturer’s instructions (all from Dako), and incubated for 1 h. Finally, the slides were flooded with peroxidase substrate solution before counterstaining with hematoxylin. Control sections were included where mAb, biotinylated anti-rat Ig, or streptavidin peroxidase complex were selectively omitted. Control slides of lung were also stained with an isotype-matched negative control antibody instead of primary antibody.

**Results**

**Cloning, Mapping, and Structural Analysis of mMCP-5.** We have used degenerated oligonucleotides and PCR to clone novel CC chemokine cDNA sequences from RNAs extracted from eosinophilia lungs (10). Three distinct groups of 150-bp PCR products (including two degenerate primers) with different nucleotide sequences were obtained (10). According to the sequence from one of them, one specific primer was designed to isolate the 5′ partial cDNA by 5′ RACE cloning strategy. The complete cDNA for this gene was then isolated by 3′ RACE cloning, which involved two further rounds of nested amplification by PCR with primers based on the nucleotide sequence of the previously cloned 5′ fragment.

The cloned full-length cDNA for this novel gene contains 540 bp, whose nucleotide sequence was confirmed by three independent PCR amplifications. It includes an open reading frame of 341 bases encoding a protein of 104 amino acids, a 5′ untranslated region of 55 bp, and a 3′ untranslated region of 145 bp (data not shown. GenBank/EMBL/DBJ accession number U50712). The mature protein is composed of 82 amino acids containing five cysteine residues (Fig. 1 A). No potential N-glycosylation sites are present in this protein. The nucleotide similarity of this gene with other CC chemokines is shown in Fig. 1 B.

The comparison of the amino acid sequence of this novel gene with those of other members of the CC chemokine family (Fig. 1 A) revealed the highest similarity with human MCP-1 and MCP-3 (Fig. 1, A and B). Because of this and other features described below, this novel mouse CC chemokine gene was named mouse monocyte chemotactic
protein-5. Comparison of mMCP-5 mature peptide with hMCP-1 mature peptide or with the first 80 amino acids of the mMCP-1/JE mature peptide revealed 65 and 45% similarity, respectively (Fig. 1). mMCP-5 is a basic protein (pI 9.07). The amino acid sequence phylogenetic tree and similarity comparisons with other CC chemokines (Fig. 1 B) showed that mMCP-5 is most similar and evolutionarily related to hMCP-1.

The mouse chromosomal location of mMCP-5, which was determined by interspecific back-cross analysis (22), revealed that the single locus encoding for this cDNA is located in the central region of mouse chromosome 11 (data not shown).

To determine the possible existence of a gene homologous to mMCP-5 in humans, a southern blot containing human genomic DNA was hybridized with an mMCP-5 cDNA probe. Under conditions of high stringency, a single hybridizing band was detected (which had a different size from that found when the same blot was hybridized with an hMCP-1 probe; data not shown), suggesting the existence of an mMCP-5 homologue in humans.

*In Vitro* Chemotactic Responses of Leukocytes to mMCP-5. To characterize the activities of mMCP-5 its expression in mammalian cells was engineered, as we have done previously (reference 10 and Materials and Methods).

Eosinophil chemotaxis to mMCP-5 was examined using mouse eosinophils (90–95% pure) purified from the peritoneal cavity of IL-5-transgenic mice (23), since normal mice do not have appreciable numbers of eosinophils. Conditioned media containing mMCP-5 recombinant protein induced migration of eosinophils in a dose-dependent manner compared to the control conditioned media (Fig. 2 A). In three independent experiments with different eosinophil and conditioned media preparations, recombinant mMCP-5

---

**Figure 1.** Comparison of the amino acid sequence of the mMCP-5 mature peptide with that of other CC chemokines and the phylogenetic tree of members of the CC chemokine family, including mMCP-5. (A) Amino acid sequence alignment of mMCP-5 with other human and mouse CC chemokines. The sequences were aligned using the Clustal method with a PAM250 residue weight table and default settings of gap penalties for pairwise and multiple alignments of 3 and 10, respectively (MegAlign; DNASTAR, Inc., Madison, WI). Amino acid sequences of the mature proteins for the hMCP-1 (35), hMCP-2 (36), hMCP-3 (37), hMCP-4 (38), mMCP-1/JE (39; 1–85 amino acids), and mEot (10) genes were compared to the amino acid sequence of the putative mature mMCP-5 protein. Amino acids identical to mMCP-5 are shaded in black with numbers across the top of the sequence referenced to mMCP-5. The cDNA sequence of mMCP-5 has been deposited in GenBank/EMBL/DDBJ under the accession number U50712. (B) Phylogenetic tree of the CC chemokine family, including mMCP-5 (bold and underlined). Distances to branch points are proportional to amino acid sequence divergence from predicted ancestral sequences. Percent similarity between the nucleotide sequence of the coding region of the amino acid sequence of the mature peptide of mMCP-5 and those of other CC chemokines are shown at the right of the figure.
from undiluted conditioned media attracted 10–19% of the input eosinophils in transwell chemotaxis assays. In parallel assays, only 1.1–2.3% of input eosinophils migrated to the control conditioned media (Fig. 2 A). Heparin/cation exchange-purified protein (see Materials and Methods) from mMCP-5–containing conditioned media induced the transmigration of ~39% (35–40% migration) of eosinophil input (Fig. 2 A).

To evaluate the chemotactic function of mMCP-5 on lymphocytes, four independent experiments were performed and showed that the conditioned media containing mMCP-5 induced the migration of lymphocytes from the bone marrow (Fig. 2 A) and from the peripheral blood (PB) (data not shown and Fig. 2 A). We failed to detect reproducible chemotaxis of LN- or spleen-derived lymphocytes to mMCP-5 (data not shown) compared to the control conditioned media. mMCP-5 attracted a subset (~2%) of lymphocytes from both the bone marrow and PB (Fig. 2 A). In a separate series of experiments, migratory lymphocytes to mMCP-5 were stained with either anti-B220 or anti-Thy1 mAbs, and the proportion of positive cells for each marker was analyzed by flow cytometry. B lymphocytes displayed a stronger response to mMCP-5 than T lymphocytes, showing a higher chemotactic index (Fig. 2 A).

Neutrophils and monocytes/macrophages used for in vitro chemotaxis assays were isolated from either normal

<table>
<thead>
<tr>
<th>A</th>
<th>Eosinophils</th>
<th>Lymphocytes</th>
<th>Monocytes</th>
<th>Neutrophils</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chemotactic Index (x)</strong></td>
<td>1.100</td>
<td>1.100</td>
<td>1.100</td>
<td>1.100</td>
</tr>
<tr>
<td><strong>Dilutions</strong></td>
<td>H.C.</td>
<td>Eotaxin (1:1)</td>
<td>Ctrl Ab(1 μg/ml)</td>
<td>Anti-MCP-5(10 μg/ml)</td>
</tr>
<tr>
<td><strong>Migration (% of Control)</strong></td>
<td>10-19%</td>
<td>1.1-2.3%</td>
<td>~39%</td>
<td>~59%</td>
</tr>
</tbody>
</table>

**Figure 2.** Chemotactic activity of mMCP-5 on mouse leukocytes in vitro and neutralization of eosinophil chemotaxis to mMCP-5 by anti-mMCP-5 antibodies. (A) The indicated mouse leukocyte subtypes were subjected to chemotaxis to different dilutions of the conditioned media containing mMCP-5 (solid diamonds) or of the control mock-conditioned media (empty diamonds). The bars and symbols show the mean and the range for one representative experiment out of three (or five for lymphocytes and monocytes). Results are expressed as chemotactic index (the ratio between the number of cells that migrated to the sample and the number that migrated to negative control, depicted as bars, axis on left of each plot) and migration (the percentage of the total number of input cells that migrated to the sample, depicted as lines, axis on the right of each plot). Positive controls (triangles) used for these experiments were rmEotaxin, rmMIP-1α, and rmIL-8. The migration of leukocytes to assay media are also included (circle). In chemotaxis assays of lymphocytes to undiluted mMCP-5–containing conditioned media (black bars) or undiluted control conditioned media (white bars), migratory cells were stained with anti-B220 or anti-Thy1 mAbs, and were analyzed by flow cytometry. (B) Eosinophil migration in response to mMCP-5 is inhibited by specific Abs. The same chemotaxis assays described in A for eosinophils were performed. The mMCP-5–containing or control conditioned media were preincubated with or without different concentrations of polyclonal antibodies against mMCP-5 (see Materials and Methods) or with rabbit Ig fraction as a control for 15 min at 37°C and, then used for chemotaxis. The chemotaxis of eosinophils to Eotaxin in the presence of the same Abs was used as control for anti-MCP-5 Ab specificity. The percentage of migration observed in the wells containing control supernatant and/or control Ab was subtracted from their corresponding experimental points. Data are expressed as the percentage of the positive control (chemokine alone), which was considered 100%.
Figure 3. mMCP-5 induced recruitment of leukocytes to the peritoneum. Peritoneal exudate was collected from C57BL/6j mice 2 h after injection of mMCP-5-containing conditioned media (closed symbols) or control conditioned media (open symbols). Each dot represents one individual mouse analyzed (10 mice per group). The bar in each panel represents the mean of the total number of cells of the leukocyte subtype indicated. For lymphocyte assays, B and T cells were also analyzed separately by immunophenotypic analysis of lymphocytes recruited to the peritoneum after mMCP-5 injection.

To attribute unequivocally all the chemotactic activity to eosinophils present in the conditioned media from mMCP-5-transfected cells to mMCP-5, we blocked it in vitro with affinity-purified polyclonal antibodies raised against an mMCP-5 peptide (see Materials and Methods). Anti-mMCP-5 antibodies were able to neutralize the migration of lymphocytes and monocytes to mMCP-5 in vitro or in vivo (data not shown).

In Vivo Peritoneal Recruitment of Leukocytes to mMCP-5. The injection of mMCP-5-containing conditioned media in mice resulted in a moderate increase in the total number of peritoneal cells that maximized (data not shown) at 2 h after mMCP-5 recombinant protein injection (2.3 ± 0.2 x 10^6 cells/mouse) when compared with the number of cells recovered from control mice injected with control conditioned media (1.7 ± 0.1 x 10^6 cells/mouse) or with PBS (1.5 ± 0.3 x 10^6 cells/mouse). In these experiments, eosinophils increased from 0.25 ± 0.13 x 10^5 of the total cells in the peritoneal exudate of control conditioned media-injected mice or PBS-treated littermates to 2.1 ± 0.6 x 10^5 in mMCP-5-containing conditioned media-injected mice.

The injection of mMCP-5 induced an increase (~1.4-fold) in peritoneal lymphocytes that was not observed in control conditioned media-injected mice (Fig. 3). mMCP-5 injection resulted in an increase in peritoneal lymphocyte numbers caused by the predominant recruitment of B220^+ B lymphocytes (5.7 ± 0.4 x 10^5 cell/mouse in mMCP-5-injected mice versus 4.4 ± 0.1 x 10^5 cell/mouse in control conditioned media-injected mice or 4.1 ± 0.2 x 10^5 cell/mouse in PBS-treated mice; Fig. 3). The number of Thy1.2^+ T lymphocytes remained comparable in these three different groups of experimental mice at the same time point indicated (5.8 ± 2.3 x 10^4; 4.9 ± 1.5 x 10^4; and 5.1 ± 1.2 x 10^4 in mMCP-5-injected mice, control conditioned media-injected mice, and PBS-treated mice, respectively; Fig. 3).

No significant increases in the total number of neutrophils or macrophages recovered from the exudates of mMCP-5-injected mice were detected at any time point analyzed (Fig. 3 and data not shown). In contrast, there were twice as many monocytes 2 h after mMCP-5 injection compared...
Figure 4. Expression of mMCP-5 under noninflammatory conditions. (A) Northern blot of mMCP-5 cDNA with RNA from different mouse organs. For confirmation of mMCP-5 expression in some organs, two separately prepared RNAs from different mice were included in the Northern blot. The size of the hybridizing band is ~0.5 kb. (B) Immunohistochemical analysis of mMCP-5 expression in lymphoid organs. Inguinal LN (I and II) and thymus (III and IV) from nonimmunized mice were stained with anti-mMCP-5 mAb (II and IV) or with an irrelevant isotype-matched negative control mAb (I and III). ×400. C, cortex; M, medulla; P, paracortex; F, follicle.

with that recovered from the exudate of mice injected with control conditioned media (Fig. 3).

Pattern of Expression of mMCP-5 under Noninflammatory Conditions. Only the LN and thymus expressed consistently high levels of mMCP-5 mRNA (~550 bp; Fig. 4 A). mMCP-5 mRNA were also found in heart, skin, lung, and spleen by RT-PCR (Fig. 4 A and data not shown), but no mMCP-5 mRNA was found constitutively in any other tissues of C57BL/6 mice (Fig. 4 A).

To determine the distribution of mMCP-5 protein in the LN and thymus, immunohistochemical analysis of sections from these organs was performed after staining with anti-mMCP-5 antibodies. In the LN, mMCP-5 staining was generally localized within stromal-type cells in the paracortex and primary follicles (Fig. 4 B, II). Few, if any, lymphocytes or dendritic cells showed immunoreactivity (Fig. 4 B and not shown). In the thymus, stromal cells predominately present in the medulla reacted to the mMCP-5 antibodies (Fig. 4 B, IV). A few cells in the cortex were stained, and there seemed to be no immunoreactive thymocytes present (Fig. 4 B and data not shown). No immunoreactivity to any cell type was recognized in either tissue using other irrelevant isotype-matched mAbs from the same hybridoma fusion (Fig. 4 B, I and III, and data not shown).

Expression and Function of mMCP-5 in the Lung during Allergic Inflammation. Northern analysis showed that mMCP-5 mRNA is markedly increased in the lungs of mice during the course of experimental lung eosinophilia (Fig. 5 A), using repeated doses of aerosolized OVA for 21 d (10). mMCP-5 mRNA expression, which was expressed at very low levels in the lung of unmanipulated mice, peaked 3 h after OVA challenge on the days analyzed (Fig. 5 A and data not shown), thus coinciding with the time point of maximal eosinophil accumulation on these days (10). Furthermore, mMCP-5 protein was localized by immunostaining to alveolar macrophages and to smooth muscle cells most strongly (Fig. 5 B). A small number of leukocytes within the large perivascular and peribronchiolar infiltrates showed low immunoreactivity (Fig. 5 B and data not shown). In areas of leukocyte localization in the lung tissue, there was an increase in reactivities of macrophages, smooth muscle cells, and other tissue resident cells that correlated with the severity of the infiltrate (not shown).

To evaluate the contribution of mMCP-5 to the development of OVA-induced lung eosinophilia, anti-mMCP-5 neutralizing Abs were administered 30 min before OVA challenge at the time of maximal eosinophil accumulation (days 20 and 21 of treatment). This antibody preparation was shown to block the transmigration of eosinophils to mMCP-5 in vitro (Fig. 2 B). Our results showed that blocking of mMCP-5 in vivo reduced by ~25% the number of eosinophils that accumulated in the BAL after OVA challenge at the same time point indicated (Fig. 5 C).

Regulation of mMCP-5 Expression In Vivo and In Vitro. Based on our previous finding (11) that the presence of lymphocytes is absolutely required for eosinophil accumulation in this model, we studied the regulation of mMCP-5 mRNA expression in the lungs of lymphocyte-deficient RAG-1 mutant mice (24). Fig. 6 A shows that there was strong reduction in the levels of mMCP-5 mRNA on days 15 and 18 in OVA-treated RAG-1 mice when compared with OVA-treated wild-type controls. It also revealed on day 21 a moderate, but notable, reduction in the level of expression of mMCP-5 in the lungs of OVA-treated RAG-1–deficient mice (n = 3; Fig. 6 A). In contrast, a comparable level of mRNA expression of Eotaxin, RANTES, and MIP-1α was found in the lung of mutant and wild-type control mice at each point during the OVA treatment (Fig. 6 A).

To investigate which lymphocyte subtype(s) could be involved in the regulation of mMCP-5 expression, North-
A

<table>
<thead>
<tr>
<th>day 15</th>
<th>day 18</th>
<th>day 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>1h 3h 6h</td>
<td>1h 3h 6h</td>
<td>1h 3h 6h</td>
</tr>
</tbody>
</table>

mMCP-5

β-actin

B

α-mMCP-5

cell Ab

color

C

Figure 5. Expression and function of mMCP-5 mRNA during OVA-induced lung allergic inflammation.

(A) At the different time points indicated after OVA administration, Northern blot analysis was performed to determine the expression of chemokines in the lung. (B) Expression of mMCP-5 protein in lungs from OVA-treated mice. Immunohistochemical analysis was performed upon lung tissue isolated on day 21 of OVA treatment using monoclonal anti-mMCP-5 (see Materials and Methods). Alveolar macrophages were prominently stained in OVA-treated mice (arrows), and smooth muscle cells (arrowheads) of the bronchioles were also densely stained in treated but not untreated mice. (×1,000). (C) Blocking of mMCP-5 protein with specific neutralizing antibodies (as used in Fig. 2 B) during the course of OVA-induced allergic inflammation (see Materials and Methods). Bronchoalveolar lavage was recovered from a treated mouse, and eosinophils were enumerated. Each dot represents a single mouse.

ern analysis was performed using RNAs from the lungs of mice lacking either T and NK cells (CD3ε-transgenic mice; 14) or CD4+ T cells (CD4-deficient mice; 25) or CD8+ T cells (CD8-deficient mice; 26) after OVA treatment. We found a comparable level of mMCP-5 mRNA expression in the lungs of these immunodeficient mice when compared with that observed in wild-type littermates during OVA treatment (Fig. 6 A and data not shown).

To address the regulation of mMCP-5 expression in different lung resident cell types present during allergic eosinophilia, we evaluated the presence of mRNA for mMCP-5 in a panel of unstimulated and stimulated cell lines and in
freshly isolated cells of different lineages by RT-PCR (Fig. 6 B) or Northern blotting (data not shown). We compared this regulation with that of Eotaxin, whose strong and inducible mRNA expression was found not to be reduced in lymphocyte-deficient mice during OVA treatment (Fig. 6 A).

No expression of mMCP-5 mRNA was found on freshly isolated peritoneal macrophages by RT-PCR (Fig. 6 B). When macrophages were stimulated in vitro with IFN-γ, but not with TNF-α, however, they expressed mMCP-5 mRNA at an easily detectable level (Fig. 6 B). Conversely, the same population of freshly isolated peritoneal macrophages stimulated with TNF-α, but not with IFN-γ, expressed mRNA for mEotaxin (Fig. 6 B). Similar results were obtained when two macrophage cell lines were analyzed (Fig. 6 B). mMCP-5 mRNA expression was found in unstimulated or LPS-stimulated P388D1 macrophages, but not in RAW287 cells (Fig. 6 B). In contrast, only RAW287 cells expressed detectable mRNA levels of mEotaxin.

Role of mMCP5 in mEotaxin-induced Eosinophil Recruitment In Vivo and In Vitro. To examine whether the presence of mMCP-5 in the eosinophilic lung, in which Eotaxin is abundantly expressed, could lead either to a larger accumulation of eosinophils or is a possible mechanism to control the inflammatory response, Eotaxin (0.5 μg/mouse) was co-injected in the peritoneum either with 400 μl/mouse (Fig. 7 A) or 800 μl/mouse (data not shown) of conditioned media containing mMCP-5 recombinant protein or with the same volumes of the control conditioned media. The total number of peritoneal eosinophils recovered from mMCP-5–injected mice or from Eotaxin–injected mice 2 h after injection was 2.2 ± 0.6 × 10^5 and 1.3 ± 0.5 × 10^5 cells/mouse, respectively (Fig. 7 A). When both chemokines were administered simultaneously, the number of infiltrating eosinophils was lower (0.8 ± 0.3 × 10^5 cells/mouse, Fig. 7 A) than that found in the peritoneal exudate of mice injected with either one alone. In contrast, when mMCP-5 and mEotaxin were administered simultaneously at very low doses (100 and 0.2 μg/mouse, respectively), the number of infiltrating eosinophils (0.5 ± 0.18 × 10^5 cells/mouse) was greater than those found when mMCP-5 or mEotaxin were injected individually at the same doses (0.09 ± 0.01 × 10^5 cells/mouse for mMCP-5 and 0.2 ± 0.03 × 10^5 cells/mouse for mEotaxin; Fig. 7 A).

To further define the chemotactic responses of eosinophils to combinations of mMCP-5 and mEotaxin, we examined them in vitro. The results from two individual experiments representative of this experimental series (n = 5) are shown in Fig. 7 B. mMCP-5 enhanced the migration of eosinophils to mEotaxin (from 3 to 10% in the presence of different concentration of mEotaxin). The maximum enhancement was reproducibly observed when 10 ng/ml of mEotaxin was combined with undiluted mMCP-5 conditioned media (Fig. 7 B). As the concentration of mEotaxin was increased from 10 to 250 ng/ml in combination with undiluted mMCP-5-containing conditioned media in the different experiments, eosinophil migration was enhanced to a lesser extent, until no mMCP-5–induced enhancement of eosinophil chemotaxis was seen at 250 ng/ml of mEotaxin (Fig. 7 B). Furthermore, mMCP-5 reduced the mEotaxin–induced eosinophil transmigration in vitro when combined with a high concentration of mEotaxin (from 50 to 250 ng/ml, depending on the experiment). This effect was not observed when the control conditioned media was combined with different concentrations of mEotaxin in the same experiments (Fig. 7 B). We have selected two experi-
Figure 7. Effect of mMCP-5 on mEotaxin-induced eosinophil migration in vivo and in vitro. (A) Peritoneal eosinophil accumulation in response to mMCP-5 and mEotaxin conjection. The number of eosinophils in the peritoneal exudate of C57BL/6J mice 2 h after injection with mMCP-5 (open circles), mEotaxin (open squares), or both chemokines simultaneously (closed circles) was determined as described in Materials and Methods. Values shown in the left panel reflect the number of eosinophils recovered from the peritoneal exudates of mice injected with 400 µl/mouse of mMCP-5-containing conditioned media and/or 0.5 µg/mouse of mEotaxin in 400 µl PBS, whereas values shown in the right panel are from mice injected with 100 µl/mouse of mMCP-5-containing conditioned media and/or 0.2 µg/mouse of mEotaxin in 400 µl of PBS. Control mice (x) injected with the same volume of control conditioned media and/or 400 µl/mouse of PBS (n = 4). Mice injected with Eotaxin (but not with MCP-5) were connected also with the same volume of control conditioned media. The bars in each panel represent the mean of the total number of eosinophils recovered from the mice analyzed (each symbol represents one individual mouse). (B) Eosinophil chemotaxis in response to combinations of mMCP-5 and mEotaxin in vitro in the transwell migration assay. Two independent experiments out of five are shown. The percentage of input cells that migrated was measured. Each experimental point was tested in duplicate. As a control, the undiluted mock-conditioned media was mixed with different concentrations of mEotaxin in parallel and used in the same assays. The upper panel represents the raw data of two representative experiments out of five that were performed. Migration is expressed as mean values and bars show duplicates. The lower panel represents the net difference between the migration (percentage of input) of eosinophils to different concentrations of mEotaxin in the presence or absence of mMCP-5 (as shown in the upper panel). The values were calculated by subtracting (individually for each concentration of Eotaxin used) the percentage of eosinophil migration induced by mEotaxin in the absence of mMCP-5 (but with the same volume of control conditioned media) from the percentage of eosinophil migration induced by mEotaxin in the presence of mMCP-5.
mMCP-5 mRNA was identified in primary cultures of macrophages or mast cells (mMCP-5) but not T lymphocytes.

In the LN and thymus, mature and immature thymocytes interact with stromal cells, and these interactions are critical for their maturation. The constitutive mRNA expression of mMCP-5 in the LN and thymus (Fig. 4 B), together with its chemotactic activity on lymphocytes, make it an interesting candidate for participation in this process. mMCP-5 does not support T or B cell proliferation in vitro (data not shown). It is notable that we detected mRNA for mMCP-5 in both skeletal and cardiac muscles (Fig. 4 A). We also found expression in heart, lung, and skin, but there was great variability between the mice that were studied.

mMCP-5 Is Different from the Other Major CC Chemokines in That Its Expression during Allergic Inflammation Is Critically Regulated by Lymphocytes. We show here that the expression of mMCP-5 mRNA in the lung is maximal 3 h after OVA challenge on all days analyzed during OVA treatment (days 15, 18, and 21). However, a clear increase in mMCP-5 mRNA levels was not seen as treatment progressed. Instead, the levels for mMCP-5 mRNA were almost constant 3 h after challenge at all time points analyzed (Fig. 5 A), contrasting with other CC chemokines in this model (10).

The pattern of mRNA mMCP-5 expression might reflect: (a) its polyspecificity, and thus it is conceivable that this chemokine could be involved in the recruitment of monocytes (which accumulate in the lung at maximum levels on day 15) and of eosinophils and/or lymphocytes (which accumulate in the lung at maximum levels on day 21) during the allergic process induced by the OVA treatment (10); or (b) different activation signals inducing chemokine expression in different cell types, for example, in mast cells, mMCP-5 is readily expressed, whereas Eotaxin is not. Blocking the mMCP-5 protein with specific antibodies in vivo during the induction of lung eosinophilia resulted in a significant decrease (~25%, P < 0.05) in the number of eosinophils that accumulated in the lung. These results indicate that mMCP-5 contributes either directly or indirectly to the development of lung eosinophilia in this model. Although other eosinophilic chemokines are expressed during the course of the OVA treatment (Fig. 6 A), mMCP-5 and RANTES are the predominant ones at earlier points of this particular inflammatory response (day 15).

Accordingly, on day 15 of the OVA treatment, the blockage of mMCP-5 with Ab revealed that at this time point, this chemokine is responsible for 80% of the accumulation of eosinophils in the lung (Gonzalo, J.A., and J.C. Gutierrez-Ramos, unpublished data).

Analysis of lung tissue from mice that were exposed to OVA (day 21, 3 h after challenge) revealed intense staining of alveolar macrophages and smooth muscle cells (Fig. 5 B) and much less intense staining of epithelial and possibly endothelial cells and fibroblasts (Fig. 5 B), which are well characterized for their ability to produce other chemokines, such as MCP-1 and MIP-1 (34). It is notable, however, that the cell type primarily responsible for Eotaxin production is the alveolar epithelium (10, 11). We failed to determine by immunostaining if mast cells have MCP-5 immunoreactivity in vivo.

A hallmark of mMCP-5, which distinguishes it from the other CC chemokines present in the eosinophilic lung, is its differential mRNA regulation during lung allergic inflammation. Only mMCP-5 mRNA expression was significantly reduced in the lung of OVA-treated, RAG-1 mutant mice (Fig. 6 A). This suggests that lymphocytes play an important role in the expression of mMCP-5 during allergic inflammation. Furthermore, similar levels of expression of mMCP-5 mRNA in the lungs of mutant mice lacking T cells (CD3e-transgenic mice, CD4-deficient mice, and CD8-deficient mice) and wild-type littermates during OVA treatment demonstrate that B lymphocytes (RAG-1-deficient mice) but not T lymphocytes are essential for mMCP-5 expression (Fig. 6 A and data not shown).

It should be emphasized that no mMCP-5 immunoreactivity was found in infiltrating leukocytes in lung sections of OVA-treated mice (Fig. 5 B), and therefore it is unlikely that the strong reduction in mMCP-5 mRNA levels in the lung of OVA-treated, RAG-1-deficient mice could be attributed directly to the absence of few, if any, mMCP-5-expressing lymphocytes. Rather, we favor the hypothesis that B lymphocytes deliver key signals to induce mMCP-5 expression by macrophages, smooth muscle cells, and/or other tissue resident cell types. This allows the hypothesis that regulation of the expression of mMCP-5 and of, for example, Eotaxin might be governed by different signals. Correspondingly, we found almost opposite patterns of expression for Eotaxin and mMCP5 mRNAs after activation of primary cultures of macrophages or mast cells (mMCP-5 mRNA can be produced by the mast cells studied here, but not Eotaxin mRNA [Fig. 6 B and reference 10]). Moreover, different mMCP-5 and mEotaxin mRNA expression was found in various cell lines representing some of the cell types studied.
lineages that may produce mMCP5 in the inflamed lung (Fig. 6 B).

The Migration of Eosinophils to Eotaxin Is Modulated by mMCP-5 In Vitro and In Vivo. Our results demonstrate that doses of either mMCP-5 or mEotaxin, which by themselves are each able to induce a significant increase in the number of infiltrating eosinophils, fail to exert the same effect when coinjected (Fig. 7 A). In contrast, doses of both chemokines that separately elicit a small but significant peritoneal recruitment of eosinophils showed a cooperative effect in the recruitment of eosinophils when simultaneously injected (Fig. 7 A). Also in vitro, our results showed that a constant amount of mMCP-5 can either enhance or reduce the chemotaxis of eosinophils to Eotaxin. Therefore, mMCP-5 modified the bell-shape curve of the response to Eotaxin (Fig. 7 B). These results suggest that mMCP-5 would cooperate with low amounts of Eotaxin in augmenting the directed movement of eosinophils in the chemotaxis assay. When a certain concentration of Eotaxin is reached in the assay, however, the presence of mMCP-5 reduces the response to Eotaxin. Experiments are underway to determine if MCP-5 and Eotaxin share a receptor on eosinophils.

Our initial work on the novel chemokine mMCP-5 has focused on the characterization of its possible function in allergic inflammatory reaction situations. The expression and function of mMCP-5 have unique characteristics during lung allergic inflammation that distinguish it from other CC chemokines studied.

The authors are indebted to Drs. B. Rollins, C. Gerard, A. Abbas, and C. Mackay for critical reading of this manuscript; to Dr. P.J. Albar for peptide synthesis, rabbit immunization, and preparation of affinity-purified polyclonal sera; to Dr. M. Kosko for advice on lymph node expression pattern; to Drs. M. Dorf, T. Schall, and B. Rollins for providing MIP-1α, RANTES, and MCP-1/JE probes, respectively. We especially thank Drs. N. Copeland and N. Jenkins for the mapping data, and Dr. Luchtmann for helpful discussions.

This work has been funded by National Institutes of Health grants HL-148675-02, DK1543, DK33506, and HL94-10-B, and by CICYT PB93-0317 and the Aplasnc Foundation of America grants. The Department of Immunology and Oncology was founded and is supported by Pharmacia and the Consejo de Investigaciones Cientificas. G-Q Jia was a recipient of a WHO-PABO fellowship. J.A Gonzalo is a recipient of postdoctoral fellowship from the Spanish Ministry for Science. J.C. Gutierrez-Ramos is the Amy C. Potter fellow.

Address correspondence to Dr. J.C. Gutierrez-Ramos, The Center for Blood Research, Inc., Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.

Received for publication 20 June and in revised form 27 August 1996.

References


